Key result
Higher serum periostin is independently linked to frailty in patients with type 2 diabetes.
Why the study?
Frailty is prevalent in type 2 diabetes, but objective biochemical markers to complement clinical screening tools remain an unmet need.
Is serum periostin associated with frailty in adults with type 2 diabetes?
Cross-Sectional (n=137)
No
Is serum periostin associated with frailty in adults with type 2 diabetes?
Serum periostin may serve as a complementary biochemical biomarker for identifying frailty in patients with type 2 diabetes.
May complement frailty screening in type 2 diabetes; hypothesis-generating and requires prospective validation before practice change.
Frailty is a multidimensional syndrome of reduced physiological reserve that is particularly prevalent in individuals with type 2 diabetes. Identifying objective biochemical markers to complement clinical screening tools, such as the FRAIL scale, is an increasingly important unmet need. Periostin, a matricellular protein involved in tissue remodeling, bone metabolism, and chronic complications of diabetes, has emerged as a potential candidate. In this cross-sectional study of 137 adults with type 2 diabetes (65 ± 8 years), participants were classified as robust, pre-frail, or frail according to FRAIL scores. Frailty correlated positively with age (p < 0.001), BMI (p = 0.006), waist circumference (p = 0.01), and diabetes duration (p = 0.040), and negatively with TBS (p = 0.001), HDL-c (p = 0.040), and eGFR (p = 0.009). A stronger positive correlation was observed with serum periostin (p < 0.001). Frail individuals showed higher periostin levels than pre-frail (p = 0.006) and robust participants (p = 0.008), independent of age. Periostin demonstrated moderate discriminatory capacity for frailty status (AUC = 0.710; p < 0.001), while adding periostin to clinical variables resulted in a numerical increase in overall model discrimination (AUC = 0.900 vs. 0.858). A threshold of >1307 pmol/L yielded 77.8% sensitivity and 66.7% specificity. These preliminary findings indicate that periostin is significantly associated with frailty in type 2 diabetes and may represent a complementary biochemical biomarker of frailty status, warranting further validation in longitudinal studies.
No takes yet. Share an insight, caveat, or question.
González-Salvatierra et al. (2026) conducted a cross-sectional in Type 2 diabetes (n=137). Serum periostin vs. Robust and pre-frail participants was evaluated on Frailty status (OR 1.003, 95% CI 1.000-1.005, p=0.025). Higher serum periostin levels were independently associated with frailty in patients with type 2 diabetes (OR 1.003 per 1 pmol/L increase, p=0.025).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: